Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Int J Clin Oncol
; 27(1): 165-174, 2022 Jan.
Article
in En
| MEDLINE
| ID: mdl-34633579
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Urinary Bladder Neoplasms
/
Carcinoma, Transitional Cell
/
Antibodies, Monoclonal, Humanized
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Aged
/
Humans
Language:
En
Journal:
Int J Clin Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Type:
Article
Affiliation country:
Japan